Latest news about Gennex Laboratories
Gennex Laboratories
10.95
0.00(0.00%)
Company Performance:
View Company Insights1D0.00%
1M+6.31%
6M-25.05%
1Y-16.48%
5Y+68.98%
More news about Gennex Laboratories
17Feb 26
Gennex Laboratories Publishes Q3 FY26 Financial Results in Newspapers Under Regulation 47
Gennex Laboratories Limited published its Q3 FY26 unaudited financial results in Business Standard and Saksham newspapers on February 16, 2026, as required under SEBI Regulation 47. The results, approved by the Board on February 14, 2026, show standalone total income of ₹3,071.23 thousands and net profit after tax of ₹445.10 thousands for the quarter ended December 31, 2025.
14Feb 26
Gennex Laboratories Appoints Ms. Khushbu Kachhawa as Independent Women Director
Gennex Laboratories Limited has appointed Ms. Khushbu Kachhawa as Additional Non-Executive Independent Women Director with effect from February 14, 2026, based on the Nomination & Remuneration Committee's recommendation. Ms. Kachhawa, holding DIN 10872432, brings 5 years of experience in business affairs and corporate secretarial matters, and her appointment is subject to shareholder approval while complying with SEBI regulations.
14Feb 26
Gennex Laboratories Independent Director Ms. Shilpa Bung Resigns Due to New Leadership Role
Ms. Shilpa Bung has resigned as Non-Executive Independent Women Director of Gennex Laboratories effective February 14, 2026, citing her new role as Chairperson of CS Hyderabad Chapter. The Board accepted her resignation in their meeting held on the same date. She confirmed no other material reasons exist for her departure and requested relief from all Board Committee memberships. Ms. Bung also serves as independent director in Sigachi Laboratories Limited and Godavari Drugs Limited.
14Aug 25
Gennex Laboratories Reports Robust Q1 Performance with 20% Revenue Growth
Gennex Laboratories Limited announced its Q1 financial results, showing significant growth. Standalone revenue increased by 20.2% to Rs 2,564.00 lacs. Standalone net profit slightly decreased by 0.4% to Rs 414.95 lacs. Consolidated revenue grew by 20.7% to Rs 3,417.75 lacs, while consolidated net profit rose by 7.7% to Rs 501.64 lacs. The company's standalone EPS remained stable at Rs 0.18, while consolidated EPS improved to Rs 0.22. Paid-up equity share capital increased to Rs 2,314.48 lacs.
Industry Peers
Sun Pharmaceutical
Divis Laboratories
Torrent Pharmaceuticals
Cipla
Dr Reddys Laboratories
Mankind Pharma
Zydus Life Science
Lupin
Aurobindo Pharma
Laurus Labs
1,880.30
(-0.11%)
6,893.00
(-0.27%)
4,429.20
(-0.69%)
1,399.50
(-0.73%)
1,321.90
(-1.00%)
2,583.90
(+3.66%)
1,040.85
(+2.15%)
2,285.50
(-0.08%)
1,517.50
(+0.31%)
1,361.10
(+1.20%)
Get More Market Insights with
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
